Tenaya Therapeutics, Inc. Operating Lease, Expense
Tenaya Therapeutics, Inc. (TNYA) reported Operating Lease, Expense of $1.20 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued
us-gaap:OperatingLeaseExpense · last filed 2022-05-11
- Tenaya Therapeutics, Inc. operating lease, expense for the quarter ending 2022-03-31 was $1.20M, a 0.00% change year-over-year.
- Tenaya Therapeutics, Inc. operating lease, expense for the quarter ending 2021-12-31 was $1.50M, a 200.00% increase year-over-year.
- Tenaya Therapeutics, Inc. operating lease, expense for the quarter ending 2021-09-30 was $1.60M, a 166.67% increase year-over-year.
- Tenaya Therapeutics, Inc. operating lease, expense for the quarter ending 2021-06-30 was $1.40M, a 133.33% increase year-over-year.
- Tenaya Therapeutics, Inc. operating lease, expense for fiscal 2021 was $5.70M, a 137.50% increase from fiscal 2020.
- Tenaya Therapeutics, Inc. operating lease, expense for fiscal 2020 was $2.40M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $1.20M 10-Q · filed 2022-05-11 | $2.70M derived: sum of 2 quarters · filed 2022-05-11 | $4.30M derived: sum of 3 quarters · filed 2022-05-11 | $5.70M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $3.10M derived: sum of 2 quarters · filed 2022-03-23 | $4.50M derived: sum of 3 quarters · filed 2022-03-23 | $5.70M 10-K · filed 2022-03-23 |
| 2021-09-30 | $1.60M 10-Q · filed 2021-11-10 | $3.00M derived: sum of 2 quarters · filed 2021-11-10 | $4.20M 10-Q · filed 2021-11-10 | $4.70M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-06-30 | $1.40M 10-Q · filed 2021-09-08 | $2.60M 10-Q · filed 2021-09-08 | $3.10M derived: sum of 3 quarters · filed 2022-05-11 | $3.70M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-11 | $1.70M derived: sum of 2 quarters · filed 2022-05-11 | $2.30M derived: sum of 3 quarters · filed 2022-05-11 | $2.90M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $1.10M derived: sum of 2 quarters · filed 2022-03-23 | $1.70M derived: sum of 3 quarters · filed 2022-03-23 | $2.40M 10-K · filed 2022-03-23 |
| 2020-09-30 | $600.00K 10-Q · filed 2021-11-10 | $1.20M derived: sum of 2 quarters · filed 2021-11-10 | $1.90M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $600.00K 10-Q · filed 2021-09-08 | $1.30M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |